An Appendix 4C release can do miracles for stocks, just look at Nexion (ASX:NNG)
Tuesday was the deadline for ASX companies to lodge their Appendix 4C (or quarterly report) with the stock market for the September quarter. This is by virtue of today being the last business day of the first month after the completion of the quarter.
Naturally, the ASX’s Market Announcements Platform is full of these announcements this morning. As well as this, the list of winners and losers is dominated by companies that had good or bad quarterlies. The company that performed the best, with a 40% share price gain, was…Nexion (ASX:NNG).

Nexion (ASX:NNG) share price chart, log scale (Source: TradingView)
Was Nexion’s Appendix 4C really that good?
Nexion is a Cloud software company that is focused on Enterprise Asset Management Solutions. The company told investors that it delivered $2.1m in revenue, a figure that has stabilised and represents over $8m on an annualised basis. Most importantly, it delivered an unaudited EBITDA of $301,000 for the quarter and also achieved a positive EBITDA result for each month in the quarter.
M&A deals coming?
Looking to its cash flows, it had a wafer-thin $4,000 positive result from operating activities and closed with $139,000 in available funding, along with a $4m funding facility that is currently on hold. Finally, the company teased investors with the prospect of M&A activity. ‘Nexion continues to investigate and has made significant progress on several M&A initiatives, but has yet to conclude any material interest’, it said.
Good news for shareholders
It has been a difficult time to be an ASX tech stock, especially a small cap company. But, some companies that are moving towards profitability have been rewarded by investors and Nexion is evidently one of them. But, there are plenty of other companies that have not done so well today.
Best of luck to all investors who have not had their companies’ quarterly released yet.
Slowly getting through the final day 4C releases… pic.twitter.com/v7sTvBnYYa
— Microcap Jesus (@Saintly96) October 30, 2023
What are the Best stocks to invest in right now?
Check our buy/sell stock tips
Blog Categories
Get the Latest Insider Trades on ASX!
Recent Posts
Immutep (ASX:IMM) wins FDA orphan status as efti Phase 2 hits 51.5% endpoint
Rebound gains fuel as FDA orphan tag backs 38-patient efti data Immutep (ASX:IMM) has received FDA orphan drug designation for…
Telix Pharmaceuticals (ASX:TLX) refinances with US$600m 2031 convert at 1.5% coupon
Raises US$600m convert, cuts refinancing risk ahead of Pixclara PDUFA Telix Pharmaceuticals (ASX:TLX) is sourcing US$600 million of convertible debt,…
Stars And Stripes Income: The 6 Best American stocks for Australian investors in 2026!
Stocks Down Under recaps tha Best American stocks for Australian investors! We know that many Australian investors look beyond the…